InflaRx N.V. (IFRX) News

InflaRx N.V. (IFRX): $2.11

0.07 (+3.43%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add IFRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#241 of 337

in industry

Filter IFRX News Items

IFRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest IFRX News From Around the Web

Below are the latest news stories about INFLARX NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.

Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing

InflaRx N.V. (IFRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | December 1, 2023

After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)

InflaRx N.V. (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Yahoo | November 28, 2023

InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

InflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | November 6, 2023

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin disease characterized by painful ulcers that can rapidly progress JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the first patient has been dosed in its P

Yahoo | November 6, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today!

William White on InvestorPlace | November 3, 2023

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part ongoingSix clinical sites initiated; first patients screened in Phase III trial of vilobelimab in pyoderma gangrenosum (PG)FDA regulatory pathway towards BLA in broader acute respiratory distress syndrome (ARDS) indication discussed in encouraging FDA Type C meetingMAA for vilobelimab for treatment of SARS-CoV-2 induced septic ARDS in critically i

Yahoo | November 1, 2023

12 Best German Stocks To Buy Now

In this piece, we will take a look at the 12 best German stocks to buy now. If you want to skip our overview of the German economy and how it has struggled as of late, then check out 5 Best German Stocks To Buy Now. The outbreak of the Russian invasion of Ukraine upended […]

Yahoo | October 31, 2023

Loss-Making InflaRx N.V. (NASDAQ:IFRX) Expected To Breakeven In The Medium-Term

InflaRx N.V. ( NASDAQ:IFRX ) is possibly approaching a major achievement in its business, so we would like to shine...

Yahoo | October 10, 2023

We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | September 13, 2023

InflaRx (IFRX) Skyrockets 110% in Six Months: Here's Why

Shares of InflaRx (IFRX) show an upward trajectory after it obtained authorization for its first-ever marketed drug, which is approved for the treatment of critically ill COVID-19 patients.

Yahoo | September 1, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!